Hammersmith Medicines Research   Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (1993)

Organization Overview

First Clinical Trial
1996
NCT01538784
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hammersmith Medicines Cumberland Avenue London NW10 7EW UK | Hammersmith Medicines Research | Hammersmith Medicines Research Cumberland Avenue London NW10 EW UK | Hammersmith Medicines Research Cumberland Avenue Park Royal London NW10 7EW, England Telephone: +44 020 8961 4130 Fax: +44 020 8961 8665 | Hammersmith Medicines Research (HMR) | Hammersmith Medicines Research Limited | Hammersmith Medicines Reserach | HMR | Trio Medicines Limited | Trio Medicines Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 1)

Aspergillosis (Phase 1)

Asthma (Phase 2)

Atrophy (Phase 2)

Bacterial Infections (Phase 1)

Barrett Esophagus (Phase 2)

Carcinoid Tumor (Phase 2)

Communicable Diseases (Phase 1)

Dyslipidemias (Phase 1)

Dyspepsia (Phase 1)

Esophagitis (Phase 1)

Esophagitis, Peptic (Phase 1)

Filariasis (Phase 1)

Gastrinoma (Phase 2)

Gastritis (Phase 2)

Gastritis, Atrophic (Phase 2)

Gastroesophageal Reflux (Phase 1)

Hyperplasia (Phase 1)

Hypertension, Pulmonary (Phase 1)

Immune System Diseases (Phase 1)

Infections (Phase 1)

Influenza, Human (Phase 2)

Lung Diseases (Phase 1)

Malaria (Phase 1)

Malaria, Falciparum (Phase 1)

Multiple Sclerosis (Phase 1)

Osteoarthritis (Phase 1)

Parkinson Disease (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Syndrome (Phase 2)

Zollinger-Ellison Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 51
  • # of Trial APIs: 45